GlassScriptPhysician profile
Ian Howard Kaden
NPI 1871560474
$4,800.01
in general payments reported to CMS, 2019-2025
24 companies · $786 in 2025
The $786 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $795 · 2020: $234 · 2021: $623 · 2022: $531 · 2023: $826 · 2024: $1,004 · 2025: $786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,617.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,616.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $1,530.24 | 2019-2025 | Idosetr, Idose |
| Allergan, INC. | $541.20 | 2019-2022 | |
| Alcon Vision LLC | $451.26 | 2019-2025 | Clareon, Clareon Panoptix Pro, Voyager Dslt |
| Sight Sciences, INC. | $355.24 | 2021-2024 | Tearcare System, Omni Surgical System |
| Bausch & Lomb Americas INC. | $294.07 | 2024-2025 | Miebo, Envista Mx60 Iol, Xiidra |
| Tarsus Pharmaceuticals, INC. | $251.45 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $221.21 | 2022-2024 | Tyrvaya |
| New World Medical,INC. | $196.33 | 2023 | |
| Carl Zeiss Meditec USA, INC. | $169.00 | 2023 | Atlas 500, Quatera 700, Iolmaster 700 |
| Abbvie INC. | $160.20 | 2022-2024 | |
| Harrow Eye, LLC | $121.11 | 2025 | Vevye |
| Apellis Pharmaceuticals, INC. | $119.01 | 2022 | |
| Mallinckrodt Hospital Products INC. | $113.26 | 2022 | |
| Ocular Therapeutix, INC. | $105.40 | 2021-2024 | Dextenza |
| Sun Pharmaceutical Industries INC. | $26.85 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $21.57 | 2023 | Iyuzeh |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Dompe US, INC. | $17.88 | 2024 | Oxervate |
| Omeros Corporation | $15.39 | 2019 | |
| Beaver-Visitec International, INC. | $15.11 | 2021 | |
| Kala Pharmaceuticals, INC. | $15.00 | 2022 | |
| Eyevance Pharmaceuticals LLC | $14.78 | 2020 | |
| Novartis Pharmaceuticals Corporation | $13.72 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $11.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ian Kaden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.